The incidence of metabolic dysfunction-associated steatohepatopathy (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has risen globally in tandem with the increase in obesity, about 30 % of the general population has MASLD. This updated terminology more accurately characterizes liver disease linked to identifiable metabolic dysfunction. According to the new definition, MASLD is characterized by hepatic steatosis and at least one of the following three criteria: overweight/obesity, T2DM, or indications of metabolic dysfunction. In addition to these comorbidities, MASLD is closely related to insulin resistance. Metabolic syndrome includes three key components: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and/or hyperglycemia.